Paul Hargreaves has been appointed Chief Development Officer (CDO), starting September 13.
He will join the management team and have a key role in the clinical development of the company’s project portfolio.
The appointment of Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to make progress with its project portfolio, it states in a press release.
“We are very happy to have Paul joining Spago Nanomedical. His extensive experience from clinical development will become a valuable asset as we are progressing and rapidly coming into clinical phase with Tumorad,” says CEO Mats Hansen.
Paul Hargreaves is a clinical pharmacologist with almost 30 years experience in clinical development in both the pharmaceutical and large CRO industry. At present, he serves as CDO with smaller Danish biotech companies, before that he held the position as Vice President, Head of Global Clinical Operations at LEO Pharma.
”I’m excited to join Spago Nanomedical at a stage where the clinical development of the company’s projects accelerates. By means of Tumorad, we can create opportunities for treatment of advanced cancers and eventually help patients in a way that is not possible today. I look forward to work with the group and take the company to the next level,” says Paul Hargreaves.
Photo: Spago Nanomedical